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Summary
Background: In Phase 3 studies of ustekinumab, a fully human monoclonal IL-12/23p40 anti-
body approved for moderate-to-severe Crohn’s disease, patients entered a long-term extension
after completing 8 weeks of induction and 44 weeks of maintenance treatment. Efficacy
through 92 weeks and safety through 96 weeks of IM-UNITI maintenance are reported.
Methods: UNITI-1 (TNF-antagonist failures) and UNITI-2 (conventional therapy failures) patients
(N = 1281) entered IM-UNITI, including 397 ustekinumab intravenous induction responders ran-
domised to subcutaneous ustekinumab 90 mg every 12 weeks, every 8 weeks, or placebo and 884
nonrandomised patients. Dose-adjustment to 90 mg every 8 weeks occurred in patients ran-
domised to 90 mg every 12 weeks and placebo patients with loss of response (Weeks 8–32). All
Week 44 completers could enter the long-term extension without further dose adjustment. Placebo
patients discontinued following study unblinding.
Results: A total of 718 patients (all treated) entered the long-term extension (298 randomised
and 420 not randomised). Overall, 86.5% (621/718) completed Week 96. The proportions of
randomised patients in clinical remission were generally maintained from Week 44 through 92 in
ustekinumab 90 mg every 12 weeks (77.4% to 72.6%), every 8 weeks (84.1% to 74.4%), and
prior dose adjustment groups (63.4% to 53.5%). At Week 92, the proportions of patients in clini-
cal remission were similar in the ustekinumab 90 mg every 12 weeks and every 8 weeks groups
and lower in patients with prior dose adjustment. Proportions of patients in clinical remission at
Week 92 for all treated every 8 weeks (64.4%) and every 12 weeks (64.3%) groups were lower
than randomised every 8 weeks (74.4%) and every 12 weeks (72.6%) groups, but similarly main-
tained. Safety events (per hundred patient-years) were similar among all placebo and ustek-
inumab patients (Week 0-96), including adverse events (484.39 vs 447.76), serious adverse
events (19.24 vs 18.82), and serious infections (4.09 vs 4.02). No dose effect was observed.
Conclusions: Subcutaneous ustekinumab maintained clinical response and remission through
Week 92. No new safety signals were observed. ClinicalTrials.gov number NCT01369355.
The Handling Editor for this article was Professor Jonathan Rhodes, and it was accepted for
publication after full peer-review.
Authors’ complete affiliations are listed in Appendix section.
Some of the data displayed in this article were presented at ECCO 2017 (oral presentation;
Barcelona, Spain) and Digestive Disease Week 2017 (poster presentation; Chicago, IL).
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1 | INTRODUCTION
Crohn’s disease is a chronic inflammatory bowel disease charac-
terised by granulomatous inflammation, most commonly involving
the terminal ileum and colon. The onset is most frequently in the
second to fourth decade with characteristic symptoms of abdominal
pain, diarrhoea, and weight loss and potential systemic and extrain-
testinal complications. Most patients have alternating periods of
relapse and remission with half of patients requiring surgery within
10 years of diagnosis. The approach to treatment has evolved from
control of symptoms to preventing progression of the disease.
Therefore, treatments that safely maintain long-term remission are
essential.1
Treatment guidelines for Crohn’s disease recommend mainte-
nance therapy after remission is achieved, particularly for moderate-
to-high risk patients.2 Potential benefits include reduction in
hospitalisation and surgery and improved quality of life.3,4 Long-term
efficacy has been demonstrated with azathioprine/mercaptopurine,5
methotrexate,6 tumour necrosis factor (TNF) antagonists,7-11 natal-
izumab,12 and vedolizumab.13 Although TNF antagonists have signifi-
cantly advanced the care of Crohn’s disease, their efficacy is
limited14 and the development of anti-drug antibodies is associated
with loss of response.15-17 In addition, potential significant side
effects of maintenance treatments include bone marrow suppres-
sion,18 malignancy,19,20 and serious infections.21,22 Therefore, a need
exists for safer agents that have demonstrated improved long-term
maintenance efficacy.
Ustekinumab is a monoclonal antibody to the p40 subunit of inter-
leukin-12 and interleukin-23 that has been approved for use in the
treatment of psoriasis, psoriatic arthritis, and Crohn’s disease.23 Both
clinical trial and registry data have confirmed the positive long-term
efficacy and safety profile of ustekinumab in psoriasis.24-26 The effi-
cacy and safety of ustekinumab in Crohn’s disease through 1 year has
been previously established in the UNITI-1 and UNITI-2 (8 weeks) and
IM-UNITI (44 weeks) studies in patients who have failed TNF antago-
nists or conventional therapies (predominantly regimens excluding
anti-TNF medications).27 Here, we report the IM-UNITI long-term
extension data demonstrating the maintenance of response and remis-
sion (Week 92) with a positive safety profile (Week 96).
2 | METHODS
2.1 | Study design and endpoints
IM-UNITI is a continuing Phase 3 ustekinumab maintenance study in
patients with Crohn’s disease. The Phase 3 programme included two
8-week, identically designed, induction studies (UNITI-1 and UNITI-
2) with distinct populations and one maintenance study (Figure 1).
The detailed study designs, eligibility criteria, and results for the
UNITI and IM-UNITI studies through Week 44 have been previously
published.27 Briefly, UNITI-1 patients were required to have received
one or more TNF antagonists at approved doses and to have met
the criteria for primary nonresponse (the absence of a response),
secondary nonresponse (a response that was not maintained), or to
have had unacceptable side effects to TNF antagonists. UNITI-2
patients were required to have failed (including unacceptable side
effects) conventional therapy (steroids or immunomodulators [mer-
captopurine, azathioprine or methotrexate]), but had not previously
failed TNF antagonists. Induction study patients were eligible to
enrol in IM-UNITI.
The primary population (randomised) for IM-UNITI comprised
397 patients from UNITI-1 or UNITI-2 who were in clinical response
at Week 8 after ustekinumab intravenous induction, defined as a
reduction from baseline in Crohn’s Disease Activity Index (CDAI) of
≥100 points or being in remission. These patients were randomly
assigned, in a 1:1:1 ratio, to receive subcutaneous injections of
90 mg of ustekinumab every 8 weeks, 90 mg of ustekinumab every
12 weeks, or placebo through Week 40 with a Week 44 primary
endpoint of clinical remission, defined as a CDAI score of <150
points. Randomised patients who subsequently met loss of response
criteria at any time between Week 8 and Week 32 were eligible to
have a single dose adjustment to ustekinumab 90 mg every 8 weeks;
these patients were evaluated 16 weeks after dose adjustment and
were discontinued from ustekinumab if not clinically improved.
The remainder of UNITI-1 or UNITI-2 patients could continue in
IM-UNITI but were not randomised and were treated as follows: Pla-
cebo induction responders continued placebo and placebo nonre-
sponders received intravenous ustekinumab 130 mg at IM-UNITI
Week 0, and continued subcutaneous ustekinumab 90 mg every
12 weeks if in clinical response at Week 8. Intravenous ustekinumab
induction nonresponders received subcutaneous ustekinumab 90 mg
at IM-UNITI Week 0 and continued ustekinumab 90 mg every
8 weeks if in clinical response at Week 8.
All patients (randomised and nonrandomised) who completed the
safety and efficacy evaluation at Week 44 were eligible to partici-
pate in the IM-UNITI extension, based upon the investigator’s opin-
ion that they would benefit from continued treatment. Throughout
the extension, patients continued to receive the same treatment reg-
imen that they were receiving at Week 44, without any further dose
adjustment. The IM-UNITI study was unblinded when the last
patient in the main study completed the Week 44 evaluations and
the Week 44 analyses were completed.
Efficacy was assessed through Week 92, with clinical remission
defined as a CDAI score of <150 points and clinical response defined
as a reduction from Week 0 of UNITI-1 or UNITI-2 in the CDAI
score of ≥100 points (or if a CDAI score of <150 was attained). Cor-
ticosteroid-free remission was defined as a CDAI score of <150
points without receiving corticosteroids at Week 92. Additional effi-
cacy evaluations in the IM-UNITI long-term extension included CDAI
and serum C-reactive protein (CRP) every 12 weeks until Week 44
unblinding and then at every dosing visit, and the Inflammatory
Bowel Disease questionnaire (IBDQ) and the 36-Item Short Form
Survey (SF-36) every 6 months. Safety was assessed every 4 weeks
through Week 96.
Patients were evaluated for antibodies to ustekinumab every
6 months. Analyses of antibodies to ustekinumab were
66 | SANDBORN ET AL.
performed using a validated, drug-tolerant electro-chemiluminescence
immunoassay, in which ustekinumab was used to capture and
detect induced immune responses to ustekinumab. Janssen or its
designee assayed these samples, under conditions in which the
identification of the patient and treatment assignment was
blinded.
2.2 | Statistical analysis
Because placebo patients discontinued the study after treatment
assignments were unblinded to investigative sites (after the
last patient completed Week 44 and database lock and subse-
quent analyses were completed), direct comparisons and/or statis-
tical comparisons of efficacy results between placebo and
ustekinumab treatment groups throughout the extension were not
possible.
Demographic and baseline disease characteristics, efficacy and
safety analyses were based on all patients treated with at least 1
administration of study agent during the long-term extension.
Descriptive statistics (eg, mean, median, standard deviation,
interquartile range, minimum and maximum) were used to summarise
continuous variables. Counts and percentages were used to sum-
marise categorical variables.
For the IM-UNITI long-term extension, three types of analyses
were conducted for remission data. Details of these analyses and
the populations included are described in Table 1. In brief, they
include (1) Analysis of patients who entered the long-term extension,
(2) Observed case analysis with inclusion only of patients who
entered the long-term extension who have data at that visit, (3)
Analysis of all randomised patients in maintenance, regardless of
whether they entered the long-term extension.
For all efficacy analyses other than the observed case analysis,
patients who had a Crohn’s disease-related surgery or discontinued
study agent due to lack of efficacy or an adverse event indicated to
be worsening Crohn’s disease after Week 44 and prior to the desig-
nated analysis time point were considered not to be in clinical remis-
sion/response, regardless of their CDAI score. Patients with
insufficient data to calculate the CDAI score at the designated analy-
sis time point were considered not to be in clinical remission/re-
sponse. Other dichotomous endpoints followed the same treatment
failure and missing data rules.
For continuous endpoints, patients meeting these treatment fail-
ure rules prior to the designated analysis time point had their induc-
tion baseline value carried forward and if there was insufficient data
to calculate the variable at the designated analysis time points their
last value was carried forward.
The incidence of antibodies to ustekinumab were summarised
for all treated patients who entered the long-term extension and
received at least 1 administration of ustekinumab, either in the
induction studies or in this study, and had appropriate samples for
detection of antibodies to ustekinumab (ie, patients with at least
1 sample obtained after their first dose of ustekinumab). Patients
Ustekinumab
90 mg SC q8w
Loss of
response
Randomised population
Clinical response
to IV ustekinumab
in induction
Ustekinumab
90 mg SC q12w
Placebo SC
Ustekinumab
90 mg SC q8w
Ustekinumab
90 mg SC q12w
Placebo SC
Ustekinumab
90 mg SC q8w prior dose adjustment
All
ustekinumab
Ustekinumab
90 mg SC
q8w
combined
Ustekinumab
90 mg SC q8w
Nonrandomised population
No clinical response to IV
ustekinumab in induction
No clinical response to IV
placebo in induction
Clinical response to IV
placebo in induction
IV ustekinumab followed
by 90 mg SC q12w
Placebo SC
Week 0 44
PE
DBL
96
DBL
272
DBL
IM-UNITI LTE
Ustekinumab
90 mg SC q8w
Ustekinumab
90 mg SC q12w
Placebo SC
R
F IGURE 1 Study design for IM-UNITI phase 3 Crohn’s disease program*. R, randomisation; IV, intravenous; SC, subcutaneous; q8w, every
8 weeks; q12w, every 12 weeks; PE, primary endpoint; LTE, long-term extension; DBL, database lock. *Unblinding occurred when the final
patients reached Week 44
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were considered positive even if antibodies were detected at any
single timepoint. The relationships between antibody to ustek-
inumab status at Week 92 and clinical response and remission
status, as well as injection-site reactions at Week 92 were
explored.
3 | RESULTS
A total of 718 patients continued into the IM-UNITI long-term
extension, of which 567 patients were treated with subcutaneous
ustekinumab 90 mg every 12 weeks (n = 213) or every 8 weeks
(n = 354). The other 151 patients received subcutaneous
placebo (Figure S1). Of the patients continuing to the long-term
extension, 84, 153 (71 with prior dose adjustment), and 61
patients on every 12 weeks, every 8 weeks, and placebo, respec-
tively, had been in the primary population, representing approxi-
mately 75% (298/397) of the original randomised, primary
population patients.
The clinical disease characteristics at Week 0 of UNITI-1 and
UNITI-2 and at Week 0 of IM-UNITI for randomised patients in the
long-term extension were generally similar among treatment groups
and representative of a population with moderately to severely
active Crohn’s disease.27 As they entered the long-term extension
(Week 44 of IM-UNITI), clinical disease characteristics of randomised
patients were generally similar for ustekinumab 90 mg subcutaneous
every 12 weeks and every 8 weeks groups and numerically higher
(eg, CDAI scores, CRP concentrations) or lower (eg, IBDQ, patients
in remission) for patients with prior dose adjustment (Table 2).
Of the 298 randomised patients who were treated in the long-
term extension, 76/298 (25.5%) discontinued study agent from
Week 44 through Week 96 (35/61 [57%] and 41/237 [17.3%] in
the placebo and all ustekinumab 90 mg subcutaneous groups,
respectively).
All patients remained blinded from Week 44 through Week 96
in the long-term extension until the study unblinding, which occurred
after completion of the Week 44 evaluations and analyses.
3.1 | Randomised patients entering long-term
extension
3.1.1 | Clinical remission Weeks 44-92
The proportions of patients in clinical remission were generally
maintained from Week 44 through Week 92 in the ustekinumab
90 mg every 12 weeks group (65/84 [77.4%] to 61/84 [72.6%]),
TABLE 1 Analyses for IM-UNITI Long-term Extension
Analysis type Population included
1. Analyses of patients who entered the
long-term extension, over first year
of long-term extension
 Pre-specified analysis
 Evaluates clinical efficacy during the first year of the long-term extension (ie, second year
of treatment, from Week 44 to 92)
 Includes two analyses:
o Intravenous ustekinumab induction responders randomised in IM-UNITI who
entered the long-term extension
o All patients who entered the long-term extension
 Patients who met a treatment failure criterion after Week 44 were considered to not be in
remission at efficacy visits from the point of treatment failure through Week 92
 Patients who had insufficient data to calculate the CDAI score were considered not to be in
remission at that visit
 Patients without corticosteroid information at Week 92 had the last available corticosteroid
dose carried forward to Week 92
2. Observed case analysis of randomised
patients who entered the
long-term extension
 Pre-specified analysis
 Patients who did not have data at a visit were excluded from analysis for that visit
 Evaluates rates of remission observed during the first year of the long-term extension
(Week 44 to Week 92) in intravenous ustekinumab induction responders randomised in IM-UNITI
who entered the long-term extension and remained on treatment at that specific timepoint
 The same treatment failure rules as described in #1 above were applied
3. ITT analysis of randomised patients from
Week 0 of maintenancea
 Post-hoc analysis
 Evaluates rates of remission through Week 92 among all intravenous ustekinumab induction
responders originally randomised in IM-UNITI
 Conservative assessment of 92 week clinical efficacy, as patients who did not enter the
long-term extension or discontinued were considered to not be in remission
 Patients who met any treatment failure criterion before or after Week 44 were considered not to
be in remission from that point onward
 Patients who had insufficient data to calculate the CDAI score were considered not to be in
remission at that visit
ITT, intent-to-treat; CDAI, Crohn’s disease activity index.
aThe efficacy population included 388 patients (excluding 9 patients enrolled prior to study restart who had received a prior investigational intravenous
formulation in induction)
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and in the every 8 weeks group (69/82 [84.1%] to 61/82 [74.4%],
respectively; Figure 2A). At Week 92, the proportions of patients
in clinical remission were similar in the ustekinumab 90 mg every
12 weeks (61/84 [72.6%]) and every 8 weeks (61/82 [74.4%])
groups and lower in patients with prior dose adjustment (38/71
[53.5%]; Table 3).
3.1.2 | Clinical remission by induction study, Weeks
44-92
The proportions of patients in clinical remission were generally main-
tained from Week 44 through Week 92 for patients from both the
UNITI-1 and UNITI-2 populations (Figure 2B).
The proportions of UNITI-1 patients in clinical remission at Week
92 were 19/32 (59.4%) in the ustekinumab 90 mg every 12 weeks
group, 19/27 (70.4%) in the every 8 weeks group and 15/32 (46.9%)
for patients with prior dose adjustment (Table 3).
At Week 92, the proportions of UNITI-2 patients in clinical
remission were 42/52 (80.8%) in the ustekinumab 90 mg every
12 weeks group, 42/55 (76.4%) in the every 8 weeks group and 23/
39 (59.0%) in patients with prior dose adjustment. In the subset of
patients who were TNF antagonist-na€ıve, data were generally consis-
tent with the overall UNITI-2 population (Table 3).
3.1.3 | Corticosteroid-free remission
The proportions of patients in clinical remission at Week 92 and not
receiving corticosteroids at Week 92 were similar in the ustek-
inumab 90 mg every 12 weeks (57/84; 67.9%) and every 8 weeks
TABLE 2 Disease characteristics of randomised patients who
entered long-term extension (at Week 44)
Placebo
Continuous
UST SC
90 mg q12w
Continuous
UST SC
90 mg q8w
Patients
with Prior
Dose
Adjustmenta
N 61 84 82 71
Median
CDAI
96.0 95.5 70.5 130.0
Median
IBDQ
180.5 189.0 185.5 171.0
Median CRP
(mg/L)
6.7 3.5 3.7 4.0
Patients in
clinical
remission
77.0% 77.4% 84.1% 63.4%
SC, subcutaneous; UST, ustekinumab; CDAI, Crohn’s disease activity
index; IBDQ, inflammatory bowel disease questionnaire; CRP, C-reactive
protein; q12w, every 12 weeks; q8w, every 8 weeks.
aPatients who were in clinical response to UST induction dosing, were
randomised, met loss of clinical response criteria from Week 8 through
Week 32, and received UST 90 mg SC q8w (this includes patients who
were randomised to 90 mg SC q8w who had a sham dose adjustment).
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UNITI-1: TNF Antagonist-failures UNITI-2: TNF Antagonist Non-failures
Ustekinumab 90 mg SC q12w Ustekinumab 90 mg SC q8w Prior dose adjustment
No. of patients (n/N)
Ustekinumab 
90 mg q12w 65/84 67/84 68/84 64/84 61/84
Ustekinumab
90 mg q8w 69/82 67/82 65/82 68/82 61/82
Prior dose 45/71 43/71 42/71 42/71 38/71
adjustment
No. of patients (n/N)
Ustekinumab
90 mg q12w 23/32 22/32 22/32 20/32 19/32 42/52 45/52 46/52 44/52 42/52
Ustekinumab 
90 mg q8w 22/27 20/27 20/27 22/27 19/27 47/55 47/55 45/55 46/55 42/55
Prior dose 16/32 17/32 17/32 17/32 15/32 29/39 26/39 25/39 25/39 23/39
adjustment
84.1
77.4
74.4
72.6
63.4
53.5
81.5
71.9
70.4
59.4
50.0 46.9
85.5
80.8
80.8
76.474.4
59.0
F IGURE 2 Clinical remission from Week 44 through Week 92 of treatment among (A) all randomised patients entering the long-term
extension and (B) by induction study subgroups. SC, subcutaneous; TNF, tumour necrosis factor; q8w, every 8 weeks; q12w, every 12 weeks
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(52/82; 63.4%) groups and were lower in patients with prior dose
adjustment (30/71; 42.3%; Table 3).
3.1.4 | Clinical response
At Week 92, the proportions of patients in clinical response were
similar for patients in the ustekinumab 90 mg every 12 weeks
(83.3%) and every 8 weeks (80.5%) groups and lower in patients
with prior dose-adjustment (67.6%) (Table 3).
3.1.5 | Change in CDAI over time from
maintenance baseline
The median change from maintenance baseline in CDAI scores for ran-
domised patients at Week 92 was 34.0 in the ustekinumab 90 mg
every 12 weeks group, 40.0 in the every 8 weeks group, and 24.0
in patients with prior dose adjustment (Table 3).
3.1.6 | Patients with normalised CRP
The proportions of randomised patients with normalised CRP levels
were generally stable from Week 44 through Week 92 in both the
ustekinumab 90 mg every 12 weeks (36.1% to 29.5%) and every
8 weeks (30.4% to 26.8%) groups (Figure 3).
3.1.7 | Patient reported outcomes
IBDQ
At Week 0 of IM-UNITI, the median IBDQ total score, IBDQ dimen-
sion (bowel, emotional, systemic, and social) scores were similar
across treatment groups (Table 4). The proportions of patients with
at least a 16-point improvement in IBDQ score from baseline of the
induction study were similar at Week 92 for patients in the ustek-
inumab 90 mg every 12 weeks (73.8%) and every 8 weeks group
(76.8%), and lower in patients with prior dose adjustment (62.0%;
Table 4).
The median change from maintenance baseline in IBDQ scores
was higher at Week 92 for patients in the ustekinumab 90 mg every
8 weeks group (9.0) as compared with patients in the every
12 weeks group (3.5), and those patients with prior dose adjustment
(6.0). The median changes from maintenance baseline in IBDQ dimen-
sion scores (eg, bowel, emotional, systemic, and social) were generally
higher for the ustekinumab 90 mg every 12 weeks and every
8 weeks groups as compared with the prior dose adjustment group.
TABLE 3 IM-UNITI efficacy assessments at Week 92 among randomised patients who entered long-term extensiona
All Patients UNITI-1 UNITI-2
Continuous
SC UST
90 mg q12w
Continuous
SC UST
90 mg q8w
Pts with
Prior Dose
Adjustmentb
Continuous
SC UST
90 mg q12w
Continuous
SC UST
90 mg q8w
Pts with
Prior Dose
Adjustmentb Combined
Continuous
SC UST
90 mg q12w
Continuous
SC UST
90 mg q8w
Pts with
Prior Dose
Adjustmentb Combined
N 84 82 71 32 27 32 59 52 55 39 94
Clinical
Remission (%)
72.6 74.4 53.5 59.4 70.4 46.9 57.6 80.8 76.4 59.0 69.1
Clinical
response (%)
83.3 80.5 67.6 68.8 81.5 56.3 67.8 92.3 80.0 76.9 78.7
Clinical remission
and not receiving
corticosteroids (%)
67.9 63.4 42.3 56.3 59.3 31.3 44.1 75.0 65.5 51.3 59.6
Clinical remission
in UNITI-1
subset N (%)c
19/32
(59.4)
19/27
(70.4)
15/32
(46.9)
19/32
(59.4)
19/27
(70.4)
15/32
(46.9)
34/59
(57.6)
Clinical remission
in the UNITI-2
subset patients
naive to
TNF antagonistsd
N (%)
29/38
(76.3)
29/39
(74.4)
18/28
(64.3)
29/38
(76.3)
29/39
(74.4)
18/28
(64.3)
47/67
(70.1)
Median change in
CDAI from
maintenance
baselinee
34.0 40.0 24.0 21.0 49.0 11.0 33.0 51.5 40.0 27.0 37.5
SC, subcutaneous; UST, ustekinumab; CDAI, Crohn’s disease activity index; q12w, every 12 weeks; q8w, every 8 weeks; Pts, patients; TNF, tumour
necrosis factor.
aPatients who had insufficient data at Week 92 are considered not to be in clinical remission or response.
bPatients who were in clinical response to ustekinumab induction dosing, were randomised, met loss of response criteria from Week 8 through Week
32 and received 90 mg SC q8w (this includes patients who were randomised to 90 mg SC q8w who had a sham dose adjustment).
cPatients refractory or intolerant to TNF antagonists (UNITI-1).
dPatients naive to TNF antagonists from UNITI-2.
ePatients who had insufficient data to calculate the CDAI score at Week 92 had their last value carried forward.
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SF-36
The median SF-36 scores at Week 0 of IM-UNITI were similar across
treatment groups (Table 4). At Week 92, comparable results were
observed among these groups in the proportion of patients with at
least a five-point improvement in both the SF-36 physical and men-
tal component scores (Table 4).
3.2 | All treated patients entering long-term
extension
3.2.1 | Remission and response Weeks 44-92
From Week 44 to Week 92, the proportions of patients in clinical
remission remained similar in the every 12 weeks (68.5% to 64.3%;
n = 213) and the every 8 weeks groups (68.9% to 64.4%; n = 354,
data not shown).
In these same groups, from Week 44 to 92, the proportions of
patients in clinical response remained similar in both the every
12 weeks (86.9% to 79.3%; n = 213) and the every 8 weeks groups
(89.0% to 75.7%; n = 354).
3.3 | Observed case analysis of randomised
patients entering long-term extension
Using observed data, clinical remission rates were also maintained
from Week 44 through Week 92 in the ustekinumab 90 mg every
12 weeks group (77.4%-79.2%), as well as in the every 8 weeks
group (84.1%-87.1%; Figure 4).
3.4 | Intent-to-treat analysis of randomised patients
from Week 0 of maintenance
Of patients originally randomised to ustekinumab 90 mg every
12 weeks, 45.0% (58/129) were in remission at Week 92, and
46.9% (60/128) of patients originally randomised to 90 mg every
8 weeks were in remission at Week 92, including 55.8% (29/52) of
patients in the TNF-antagonist na€ıve subset. Consistent with other
analyses, remission rates were sustained from Week 44 through
Week 92 (Figure 5).
3.5 | Safety in all treated patients entering
long-term extension
3.5.1 | Weeks 0-96
Safety events (per hundred patient-years) were similar among all
ustekinumab-treated patients compared to placebo, including over-
all adverse events (484.39 vs 447.76), serious adverse events
(19.24 vs 18.82), and serious infections (4.09 vs 4.02), with 244.2
patient-years of follow-up among placebo-treated patients and
1020.0 patient-years years among all ustekinumab-treated patients.
The number of adverse events, serious adverse events, and serious
infections per hundred patient-years were generally comparable for
the ustekinumab 90 mg every 12 weeks and every 8 weeks
groups, without dose effect (Table 5).
3.5.2 | Weeks 44-96
Safety events (per hundred patient-years) were similar among all
ustekinumab-treated patients compared to placebo, including overall
adverse events (401.27 vs 371.84), serious adverse events (24.27 vs
19.56), and serious infections (5.20 vs 3.73), with 115.4 patient-
years of follow-up among placebo-treated patients and 536.8
patient-years years among all ustekinumab-treated patients. No dose
effect was seen.
One case of tuberculosis deemed unrelated to study drug by the
investigator was reported in a 45-year-old male from South Africa
who received ustekinumab every 8 weeks during the long-term
extension. Although negative for tuberculosis during screening at
study entry and asymptomatic, the patient had a positive Quanti-
FERON-TB Gold test on routine annual screening and had bronchial
brushings that were positive for mycobacterium tuberculosis. The
patient completed 6 months of therapy for tuberculosis with com-
plete resolution. A single, serious opportunistic infection of cytome-
galovirus colitis occurred in a 32-year old who received ustekinumab
induction followed by placebo maintenance (440 days after last
exposure to ustekinumab). The patient was treated with ganciclovir
with resolution of the infection.
The number of treatment-emergent malignancies per hundred
patient-years of follow-up was 2.60 for placebo patients, and 0.37
for ustekinumab patients. Five malignancies were reported in
patients during the long-term extension. One squamous cell cuta-
neous carcinoma in a patient randomised in maintenance to pla-
cebo and who continued to receive placebo in the long-term
extension; one testicular seminoma in a 31-year-old male ran-
domised in maintenance to ustekinumab 90 mg subcutaneous
every 8 weeks; and one basal cell carcinoma in a patient who was
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TABLE 4 Inflammatory bowel disease questionnaire (IBDQ) and 36-item short form survey (SF-36) scores at baseline, Week 44, and Week
92
Continuous SC
UST 90 mg
q12w
Continuous SC
UST 90 mg
q8w
Patients with
Prior Dose Adjustmenta All UST treated
IBDQ
N 84 82 71 237
Median baseline score 175.0 179.0 175.0 178.0
Median change from baseline
at Week 44
8.0 5.0 1.0 5.0
Median change from baseline
at Week 92
3.5 9.0 6.0 6.0
Patients with ≥16-point improvement
at Week 92
73.8% 76.8% 62.0% 71.3%
Bowel
N 84 82 71 237
Median baseline score 57.0 57.5 54.0 56.0
Median change from baseline at Week 92 1.0 3.0 2.0 2.0
Emotional
N 84 82 71 237
Median baseline score 65.5 66.0 64.0 66.0
Median change from baseline at Week 92 1.5 4.0 1.0 2.0
Systemic
N 84 82 71 237
Median baseline score 24.0 25.0 25.0 25.0
Median change from baseline at Week 92 1.0 2.0 0.0 1.0
Social
N 84 81 71 236
Median baseline score 31.0 31.0 30.0 31.0
Median change from baseline at Week 92 1.0 1.0 0.0 1.0
SF-36
PCS
N 76 75 69 220
Median baseline score 49.50 50.12 48.36 49.54
Median change from baseline at Week 44 1.92 0.88 0.31 0.96
Median change from baseline at Week 92 1.21 2.93 0.81 2.02
Patients with a 5-point improvement
at Week 92
59.2% 69.3% 59.4% 62.7%
MCS
N 76 75 69 220
Median baseline score 48.69 49.43 49.95 49.38
Median change from baseline at Week 44 3.34 2.00 0.04 1.79
Median change from baseline at Week 92 2.80 2.51 1.68 0.89
Patients with a 5-point improvement
at Week 92
65.8% 62.7% 49.3% 59.5%
SC, subcutaneous; UST, ustekinumab; q12w, every 12 weeks; q8w, every 8 weeks; PCS, Physical Component score; MCS, Mental Component score.
aPatients who were in clinical response to ustekinumab (UST) induction dosing, were randomised, met loss of response criteria from Week 8 through
Week 32 and received 90 mg SC q8w (this includes patients who were randomised to 90 mg SC q8w who had a sham dose adjustment).
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not randomised but received ustekinumab 90 mg subcutaneous
every 12 weeks during the long-term extension. Two malignancies
(papillary thyroid cancer and squamous cell cutaneous carcinoma)
were reported in two patients who were not randomised and did
not receive ustekinumab throughout the entire study.
Three deaths were reported, two of presumed cardiovascular
causes and one suicide. Two of the three patients received ustek-
inumab 90 mg every 8 weeks and one patient received ustekinumab
90 mg every 12 weeks.
The proportions of patients with 1 or more injection-site reac-
tions was 2.0% (n = 11) for ustekinumab patients and 0.6% (n = 6)
for placebo patients with no reports of serious reactions, anaphylaxis
or serum sickness-like reactions.
3.6 | Immunogenicity in randomised patients
entering long-term extension
A total of 237 randomised patients who received ustekinumab dur-
ing the long-term extension had appropriate samples for antibody to
ustekinumab status through Week 96. Across all randomised treat-
ment groups, 4.2% (10/237) of ustekinumab subcutaneous-treated
patients were positive for antibodies to ustekinumab. Among
patients on continuous 90 mg every 8 weeks treatment, the rate of
antibodies to ustekinumab was 2.4%, similar to the rate seen in this
group at 44 weeks.27 Of note, rates of antibodies to ustekinumab
were higher among patients who were randomised to placebo (8.2%;
5/61).
4 | DISCUSSION
IM-UNITI is the 5-year maintenance study in the Phase 3 pivotal
programme for treatment of patients with Crohn’s disease with
ustekinumab. As previously shown, through 44 weeks of treatment,
statistically significant evidence was generated demonstrating that
treatment with subcutaneous ustekinumab 90 mg every 12 weeks
or every 8 weeks was effective in maintaining clinical response and
remission in patients with moderate-to-severe Crohn’s disease.27
Our findings confirm that in ustekinumab induction responders,
remission, and response rates were maintained through Week 92 of
the study in both TNF antagonist-refractory patients from UNITI-1
and UNITI-2 conventional therapy failure patients (predominantly
TNF antagonist-na€ıve). However, maintenance of remission from
Week 44 to Week 92 of subcutaneous ustekinumab was slightly
lower in the UNITI-1 subset. Efficacy from Week 44 to Week 92 of
subcutaneous ustekinumab maintenance in patients entering the
long-term extension was similar for both the every 8 weeks and
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every 12 weeks subcutaneous ustekinumab dose regimens, in both
populations. In a combined analysis that included all randomised
treatment groups, patients who had previously met loss of response
criteria for dose adjustment before Week 44 had somewhat lower
remission rates over the second year of treatment. Similar and con-
sistent efficacy was observed for every 12 weeks and every 8 weeks
dosing as measured by proportions of patients with normalised CRP
and in those experiencing improvements in IBDQ and SF-36 health-
related quality of life. Discontinuation rates were low, with over
90% of all patients completing Week 96 of the extension trial.
Many controlled maintenance studies of biological agents have
been limited to 1 year or less in duration,7,8,11,12 with the exceptions
of adalimumab and vedolizumab.9,10,13 Recognising the challenges of
cross-study comparisons, due to differences in study populations,
efficacy measures, statistical analysis, and study designs, it is difficult
to compare these results with previous adalimumab or vedolizumab
long-term extension data. However, the maintenance of efficacy
with ustekinumab in patients with Crohn’s disease was stable over
92 weeks of treatment. This experience of ustekinumab in patients
with Crohn’s disease is consistent with that seen with maintenance
of efficacy and excellent retention through 5 years reported from
the ustekinumab psoriasis Phase 3 studies28,29 and superior ustek-
inumab drug survival rates compared to TNF antagonists in the large
psoriasis PSOLAR registry.26
Variability in efficacy from Weeks 44 to 92 of the long-term
extension was seen, depending on the analysis and the treatment
group. Not unexpectedly, remission rates were higher with an as-
observed analysis. Remission rates were lower if all responders who
entered IM-UNITI were included in the analysis as opposed to only
those who entered the long-term extension. However, even with this
most stringent analysis, remission rates remained stable in the study,
with the clinically important observation that, even when analysed in
this conservative fashion, approximately one-half of induction
responders were in remission at Week 92. These results are consis-
tent with a recently published retrospective multicentre cohort study
of 122 refractory Crohn’s disease patients who were treated with
ustekinumab with a median follow-up of 26.6 months.30
In general, patients who had not failed an anti-TNF therapy
(UNITI-2) demonstrated higher rates of remission at Week 92, con-
sistent with the Week 44 results.27 While results were generally
consistent between every 8 weeks and every 12 weeks treatment
groups from Week 44 to Week 92, differences seen at Week 44
were generally sustained through Week 92. Clinical efficacy was
consistently lower across endpoints for those patients who dose-
adjusted before entering the long-term extension. Perhaps not sur-
prisingly, upon entry into the long-term extension, these patients
(who had already previously met loss of response criteria prior to
Week 44) had notably higher median CDAI scores, higher median
CRP concentrations, lower median IBDQ scores, and lower rates of
clinical remission, indicating that they are a subset with more severe
disease. Among all treated patients (incorporating these patients as
well as the nonrandomised and randomised groups), rates of
response and remission were also slightly lower than the randomised
every 8 weeks and every 12 weeks groups, but were similarly main-
tained. While some data have been published on predictors of
response to ustekinumab in Crohn’s disease patients, further analy-
ses to identify patients who are most likely to achieve maximum
benefit from ustekinumab would be helpful.31
Rates of patients who developed anti-drug antibodies were low
and formation of antibodies did not impact response and remission
rates. In randomised patients who received continuous treatment,
the number of patients with anti-drug antibodies remained low and
was consistent from Week 44 through Week 96.27 Randomised
patients who received an induction dose of ustekinumab followed
by placebo had higher rates of antibodies, suggesting that drug
exposure followed by a significant gap in treatment may increase the
risk of antibody formation. However, even this proportion with anti-
bodies (8%) is low compared to anti-drug antibody rates seen with
other approved Crohn’s disease biologics,32 particularly when those
drugs are assessed using similar high sensitivity, drug tolerant assays.
TABLE 5 Summary of key safety finding per hundred patient-years of follow-up from Week 0 through Week 96: all patients who entered
long-term extensiona
Placebo SC UST 90 mg q12w
SC UST 90 mg
q8w All UST
N 151 213 354 567
Average duration of follow-up (weeks) 84.1 93.8 93.4 93.5
Total patient-years of follow-up 244.2 384.3 635.6 1020.0
Deaths 0 1b 2 3
Number of specified events per hundred patient-years of follow-up (95% confidence interval)
Adverse events 484.39 (457.18, 512.80) 413.70 (393.62, 434.55) 468.36 (451.68, 485.49) 447.76 (434.87, 460.94)
Serious adverse events 19.24 (14.14, 25.59) 19.51 (15.35, 24.46) 18.41 (15.22, 22.06) 18.82 (16.26, 21.68)
Infections 105.64 (93.14, 119.35) 112.66 (102.30, 123.79) 120.51 (112.13, 129.36) 117.55 (110.99, 124.40)
Serious infections 4.09 (1.96, 7.53) 5.72 (3.59, 8.67) 2.99 (1.80, 4.67) 4.02 (2.88, 5.45)
SC, subcutaneous; UST, ustekinumab; q12w, every 12 weeks; q8w, every 8 weeks
aData are based on all randomised and nonrandomised patients combined by regimen who entered the long-term extension
bDeath occurred in a nonrandomised patient on q12w UST after withdrawal of consent
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While patients in this long-term extension were not subject to
dose escalation based on drug concentrations, a previous analysis of
ustekinumab serum concentrations of UNITI-1, UNITI-2 and through
Week 44 of IM-UNITI demonstrated a relationship between serum
concentrations and efficacy.33 This supports the use of the every
8 weeks dose regimen or the option to dose escalate if patients who
start every 12 weeks dosage fail to achieve response or lose
response, as was allowed before Week 44 of IM-UNITI. However,
future studies are needed to evaluate whether proactive therapeutic
drug monitoring of ustekinumab to target levels improves long-term
Crohn’s disease outcomes. Of note, in contrast to TNF antagonists, in
the previous study,33 there was no significant impact of co-treatment
with immunomodulators on serum concentrations, possibly related to
the low immunogenicity of ustekinumab.
In the study extension through Week 96, ustekinumab was well-
tolerated with a favourable safety profile that did not differentiate
from placebo. Among all treated patients, events per hundred patient-
years of adverse events, serious adverse events, and serious infections
were similar among the every 12 weeks and every 8 weeks groups,
individually, with no evidence of a dose effect. Between the two dose
groups and among combined ustekinumab groups, there was no differ-
ence in the number of these events compared to placebo. No serious
opportunistic infections occurred in ustekinumab-treated patients
from Week 44 to Week 96. A nonserious infection of pulmonary
tuberculosis occurred in a patient living in a region endemic for tuber-
culosis and who received ustekinumab every 8 weeks during the study
extension. Rates of injection-site reactions remained low with no
reports of serious reactions, anaphylaxis, or serum sickness-like reac-
tions. Rates of malignancy were not increased. Three deaths were
reported during the study extension with an observed rate of death
comparable to the rate of death in a large cohort study of patients with
Crohn’s disease.34
There are limitations in the study extension design. First, patients
were selected by the investigator to participate in the study exten-
sion because in their opinion, they might benefit from continued
treatment (although 97.5% [719/737] of patients that reached Week
44 did so). This criterion may limit the generalisability of the findings
to only those patients who responded to and tolerated ustekinumab
through approximately 1 year of treatment. Second, because
patients who entered the study extension on placebo represent a
group of patients who were long-term responders to ustekinumab
induction or were true placebo responders and were therefore dis-
continued from the study when unblinding occurred, direct efficacy
and statistical comparisons between placebo and ustekinumab treat-
ment groups could not be performed over the long-term extension
duration. Hence, the emphasis of this manuscript is on efficacy mea-
sures among ustekinumab-treated patients.
In summary, patients with moderately to severely active Crohn’s
disease, who received ustekinumab in the study extension, main-
tained clinical response and clinical remission through Week 92 of
IM-UNITI. Clinical results were supported by maintained normalisa-
tion of CRP concentrations and improved health-related quality of
life outcome measures. The safety profile observed for ustekinumab
through Week 96 of treatment was consistent with the safety
through Week 96 and with the established safety profile within the
ustekinumab prescribing information with no new safety signals
identified. Additional efficacy and safety data from IM-UNITI will
continue to be generated through 5 years of maintenance.
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